|
Dear Reader :
This month’s newsletter, co-developed by the IPA and Citeline, spotlights important developments in the biosimilars space and also what US FDA Commissioner Robert Califf’s top priorities are in 2024.
We tell you about the EMA’s concept paper on re-evaluating the need for comparative efficacy studies to support biosimilar applications and the FDA chief’s views on combating medical misinformation.
There’s also a piece on biopharma’s collective crystal ball in the funding, M&A and partnering arena.
Anju Ghangurde - Executive Editor (Asia Pacific), Scrip/Pink Sheet
Dr. Shridhar Narayanan - Senior Technical Advisor - Innovation, IPA
|
